×

RNS Number : 0462L

Midatech Pharma PLC

20 December 2018

 

 

 

 

 

 

 

 

20 December 2018

Midatech Pharma PLC

("Midatech", "Company" or "Group")

 

Midatech Announces Q-Sphera™ Microsphere Technology Partnership

–      Collaboration agreed with major regional pharmaceutical company

–      Midatech's leading technology will be used in development and evaluation with a key clinical program

–      Further validates Q-Sphera™ sustained release drug delivery technology

 

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, today announces an agreement with a major regional corporation ("the Partner"), in which the Partner will evaluate Midatech's Q-Sphera™ microsphere sustained release technology for use with the Partner's materials.

 

Under the collaboration agreement, the Partner will conduct a feasibility program using Midatech's Q-Sphera™ technology. No financial terms have been disclosed.

 

The agreement follows the positive clinical 'proof-of-concept' in August this year for Q-Sphera™ as a sustained release drug platform in the MTD201 first-in-human study. This study was a key inflection and validation point for both the Q-Sphera™ technology, as well as its application in a therapeutic product MTD201 for carcinoid cancer and acromegaly.

 

Q-Sphera™ is the next generation micro-encapsulation and polymer-depot sustained release (SR) drug delivery platform developed by Midatech using a novel and disruptive printing-based process, with significant and distinct advantages over conventional technologies.  From a manufacturing perspective Q-Sphera™ is an improved precise, scalable, efficient, and environmentally friendly microparticle manufacturing platform. From a clinical profile perspective it ensures homogenous microparticles that release active drug compounds into the body in a linear, well controlled and predictable manner over an extended period of time. Finally, from a convenience perspective Q-Sphera allows simpler and quicker reconstitution, improved injectability and less painful injections due to the smaller needle size required.

 

The global controlled release market size is in the order of $32bn, and the current market for sustained release microsphere products is approximately $6bn pa1 which includes blockbuster drugs for oncology, hormonal disorders, autoimmune diseases, various mental health disorders, alcohol/ drug dependence and pain management.

 

Commenting on the announcement, Dr Craig Cook, Chief Executive Office of Midatech Pharma, said: "We are delighted to announce this partnership with a leading global pharmaceutical corporation.  This marks another important step in the development of our impressive Q-Sphera™ technology, after the positive clinical 'proof of concept' first-in-human study earlier this year in carcinoid cancer and acromegaly. Together with partnerships such as the one being announced we are focused on increasing our traction in the sustained delivery market, where we hope to establish Q-Sphera as the leading platform.  Our innovative sustained release technology has the potential to improve the efficacy, safety and convenience of existing drugs by enabling improved clinical release profiles of drugs. We look forward to the results of this feasibility collaboration, as well as further developing the platform and working with this partner and others looking to capture a share of the multibillion dollar market for sustained release treatments."

 

1 Transparency; Grandview; GlobalData Research

– Ends –

 

For more information, please contact:

 

Midatech Pharma PLC

Craig Cook, CEO

+44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate finance: Freddy Crossley / Emma Earl

Corporate broking: James Stearns

+44 (0)20 7886 2500

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Nicholas Brown / Angela Gray

+44 (0)20 3709 5700

[email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

+1 339 970 2843

[email protected]

 

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech Pharma (LSE AIM: MTPH; NASDAQ: MTP) is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing a range of improved chemo~therapeutics or new immuno~therapeutics, using its three proprietary platform drug delivery technologies, all of which are in the clinic, specifically: 

1.    Q-Sphera™ platform: our disruptive polymer microsphere technology used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months.

2.    MidaCore™ platform: our leading edge gold nanoparticle technology used for targeting sites of disease at the nanoscale i.e. i. chemotherapy – improved and targeted delivery of existing chemotherapeutic agents to tumour sites, as well as ii. immunotherapy – enhanced uptake of new immuno-moieties by immune cells that can then mount an immune attack against cancer cells

3.    MidaSolve platform: our innovative nanosaccharide technology used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumours

Each of our three technologies are thus focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can exert their actions in an effective, safe and precise manner.

Midatech is headquartered in Oxfordshire, with an R&D facility in Cardiff and a manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

AGRFKCDDDBDBFBD

Close

×

RNS Number : 8897K

Osirium Technologies PLC

19 December 2018

 

 

For immediate release

19 December 2018

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

Contract win with major international provider of Financial Services

 

Osirium Technologies plc (AIM: OSI.L), a leading vendor of cloud-based cybersecurity software, is pleased to announce a contract win with a leading international provider of fiduciary and administration services.

 

Under the terms of the contract Osirium will deliver its full PxM Platform including the Privileged Account Management, Privileged Task Management and Privileged Session Management modules and associated consultancy services.  The initial licence is for 400 devices and is set to run for 39 months.

 

The Osirium solution is being implemented to address a range of business and operational challenges, including:

 

·     automating tasks to simplify and secure routine and frequently-used activities, as well as to deliver time and cost savings;

·     providing control over internal access for system administrators and shared partner logins;

·     controlling and protecting passwords against Phishing and Malware attacks;

·     auditing and monitoring user access and activity to demonstrate compliance with GDPR and other regulations.

 

David Guyatt, Chief Executive Officer, commented: "Osirium is delighted to have been awarded this contract. The wide range of business challenges and use cases that we will be addressing  demonstrates the continuously increasing value our innovative approach to cybersecurity delivers to customers."

 

–      Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Alex Price
Yellow Jersey PR (Financial PR) Sarah Hollins Henry Wilkinson	Tel: +44 (0)7764 947 137 Tel: +44 (0)7951 402 336

 

 

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI.L) operates in one of the fastest growing parts of the cybersecurity market and is a leading vendor of Privileged Access Management ("PAM") software. Osirium's cloud-based products protect critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation PAM solution.  The team has developed the concept of a Virtual Air Gap to separate users from passwords.  Built on Robotic Automation technology, Osirium's Privileged Task Management module further strengthens Privileged Account security by minimising the cyber-attack surface and delivering an impressive return on investment benefits for customers.

 

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTBLBDDISBBGII

Close

×

RNS Number : 5868K

FireAngel Safety Technology Group

17 December 2018

 

17 December 2018

 

FireAngel Safety Technology Group plc

("FireAngel" or the "Company")

 

Contract wins

 

FireAngel (AIM: FA.), one of Europe's leading developers and suppliers of home safety products, announces that it has secured agreements to supply mains and battery-powered smoke and heat alarms to two housing associations in Scotland.

 

The Company will supply River Clyde Homes, a not-for-profit affordable housing provider with 5,800 homes, with a mix of mains and battery products. It has also signed a two-year agreement with Caledonia Housing Association, which owns and manages over 4,000 homes, to supply a mix of mains and Wi-Safe 2 battery alarms, which are all compatible with the Company's connected home solutions. This contract, along with the previously announced contract with Queens Cross Housing Association, has been secured through the Scottish Procurement for Housing framework.

 

Following changes to the Housing (Scotland) Act, expected to be enacted early in 2019, all homes in Scotland will require:

·    sealed long-life battery or mains-wired alarms that are interlinked;

·    one functioning smoke alarm in the room that is frequently used by the occupants in the daytime;

·    one functioning smoke alarm in every circulation space on every floor;

·    one heat alarm in every kitchen; and

·    a carbon monoxide alarm will also need to be fitted in each room with a carbon-fuelled appliance or flue.

 

FireAngel's Wi-Safe 2 wireless interlink alarms ensure that each property achieves constant compliance through the use of interlinked alarms installed in the kitchen, hallway and living room. Additionally, FireAngel's unique monitoring platform, FireAngel Connect, allows for remote monitoring and instant notifications.

 

Neil Smith, Group Chief Executive of FireAngel, commented: "We are delighted to have signed two further contracts with housing associations in addition to our Queens Cross Housing Association agreement. Our alarms are designed to provide the highest level of protection at all times and to ensure compliance with the imminent new legislative changes requiring interlinked alarms in all properties. It is encouraging to see housing associations in Scotland recognising the imminent implementation of legislation and the need to ensure the products they are seeking to install are compliant with the upcoming regulations."

 

 

For further information, please contact:

 

FireAngel Safety Technology Group plc	02477 717 700
Graham Whitworth, Executive Chairman
Neil Smith, Group Chief Executive
Stockdale Securities Limited	020 7601 6100
Tom Griffiths
Vigo Communications	020 7390 0233
Jeremy Garcia / Fiona Henson / Charlie Neish

 

Notes to Editors

 

About FireAngel Safety Technology Group plc ("FireAngel")

 

FireAngel's mission is to protect, save and improve our customers' lives by making innovative, leading edge technology simple and accessible.  FireAngel is one of the market leaders in the European home safety products market and launched its own connected homes product proposition at the end of 2016. 

 

FireAngel's principal products are smoke alarms, CO alarms and accessories.  The Company has an extensive portfolio of patented intellectual property in Europe, the US and other selected territories.  Products are sold under FireAngel's leading brands of FireAngel, FireAngel Pro, AngelEye and FireAngel Connect.

 

For further product information, please visit: www.fireangeltech.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAFFSFMLFASEDE

Close

×

RNS Number : 6039K

Concepta PLC

17 December 2018

 

17 December 2018

Concepta Plc

("Concepta" or the "Company")

myLotus® successful UK launch

 

Concepta Plc (AIM: CPT), the innovative UK healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market is pleased to advise on the successful launch in the UK of its breakthrough myLotus®  product for women's fertility.  

myLotus® allows women to self-test to identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure personalised hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app.  

Whilst awareness, profile and sales of the myLotus® device are just commencing, feedback from early users and fertility bloggers has been very positive can be viewed online at www.myLotus.com

Discussions have also commenced with 'Key Opinion Leaders' to advise on the wider use of myLotus® especially for women who wish to carefully monitor their hormonal levels and for those who have previously struggled to conceive naturally, enabling an alternative for couples prior to considering more costly IVF treatment.   

In addition to the growing myLotus® digital UK presence, the Company is preparing plans for the roll-out of myLotus® across Europe under its CE-mark approval. Commercial discussions have also commenced with retail providers to make myLotus® more broadly available across the UK.

Matthew Walls, Chairman said: "Although marketing and communications around myLotus® are just beginning, feedback from the early users has been exceptional. We will be raising awareness of the value of the myLotus® device and its window on fertility over the coming months via an increased online presence, Key Opinion Leaders and marketing of our initial fertility case studies. Further details can be viewed at www.myLotus.com."

 

Enquiries

Company: www.conceptaplc.com, Product: www.myLotus.com

Matthew Walls, Chairman

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Novum Securities

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey PR Limited (Financial PR)

Felicity Winkles Tel: +44 (0) 774 884 3871

 

About Concepta Plc:

Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on increasing a woman's chances of getting pregnant naturally and for unexplained infertility in women.

myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to help women conceive naturally by identifying their window of fertility and optimal time for conception.

The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.

myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF typically not offered until two years. Research indicates couples start to take positive action ahead of this time with little medical support to help them do so.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

PRLUNUKRWOAUAAA

Close

×

RNS Number : 5651K

Xeros Technology Group plc

17 December 2018

 

RNS Reach

17 December 2018

 

Xeros Technology Group plc

 

MARKEN establishes a unique position in US firefighter's personal protective equipment servicing market

 

Xeros Technology Group plc (AIM: XSG, 'Xeros', 'the Group'), the developer and provider of water saving technologies with multiple commercial applications, today announces that MARKEN, its North American high performance workwear business specialising in the cleaning, inspection and repair of firefighter's personal protective equipment ('PPE'), has become the only Independent Service Provider ('ISP') in North America to secure UL DQS ISO ISO-9001 registration, recognising the company's highest standards of quality management.

 

The UL DQS ISO ISO-9001 registration has been secured for each of MARKEN'S sites in North America: North Las Vegas, Nevada; Austell, Georgia; Medley, Florida and Corona, California.

 

Additionally, MARKEN has become one of only a handful of ISPs to secure verification under both US National Fire Protection Association ('NFPA') 1851 and 1855 standards, covering structural, proximity and technical rescue PPE used by fire departments. The verifications allow MARKEN to clean, decontaminate, inspect and repair every element of a firefighter's PPE such as jackets, trousers, boots and helmets, using Xeros' unique, patented technologies.

 

Joey Beeman, General Manager of MARKEN commented:

 

"The welfare of the more than a million permanent and volunteer firefighters across the US is of paramount importance to us in developing MARKEN's service offering. With serious concerns about how firefighters are repeatedly exposed to dangerous situations and toxic carcinogens while in the line of duty, it's more important than ever to ensure their protective clothing and equipment is effectively cleaned, decontaminated and maintained to ensure it is kept in prime condition.

 

"Securing ISO registration recognises that MARKEN is driving up standards across the US market for the cleaning and maintenance of firefighter's clothing and specialist protective equipment.

 

"With both ISO and NFPA verification, MARKEN is rapidly establishing a reputation as the market leader in the US for the cleaning and maintenance of firefighter PPE.

 

"We are seeing considerable interest from fire departments across North America – acknowledging the clear benefits of MARKEN's higher standards of operation and Xeros' unique cleaning technologies in developing cost-effective and sustainable solutions for the cleaning and decontamination of firefighter PPE."

 

MARKEN is the only service provider operating in coast-to-coast locations in North America to hold UL DQS ISO 9001 registration and both UL NFPA 1851 and 1855 verification.

 

 ENDS

 

Enquiries:

 

Xeros Technology Group plc   Mark Nichols, Chief Executive Officer   Paul Denney, Chief Financial Officer	Tel: 0114 321 6328
Jefferies International Limited (Nominated Adviser and Joint  Broker)   Simon Hardy / Will Soutar	Tel: 020 7029 8000
Berenberg (Joint Broker)   Chris Bowman / Ben Wright / Laure Fine	Tel: 020 3207 7800
Instinctif Partners   Adrian Duffield / Kay Larsen/ Chantal Woolcock	Tel: 020 7457 2020

 

Notes to Editors

 

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes.

 

Xeros' uses its patented XOrbTM technologies to significantly reduce the amount of water used in a number of major applications with the remaining water becoming far more efficient in either affixing or removing molecules from substrates such as fabrics and garments. The result being significant improvements in economic, operational and sustainability outcomes.

 

Xeros has three divisions working in the garment finishing (Textile Technologies), tanning (Tanning Technologies, branded Qualus) and cleaning/laundry (Cleaning Technologies) markets. In cleaning/laundry, the company has three applications covering domestic laundry, commercial laundry (branded "Hydrofinity") and the cleaning of high performance workwear (branded "Marken").

 

For more information, please visit – http://www.xerostech.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRABXBDDXGBBGIS

Close

×

RNS Number : 3171K

Integumen PLC

13 December 2018

 

13 December 2018

 

Integumen plc

 

("Integumen" or "the Company")

Labskin-On-A-Chip to monitor real-time skin related diseases and Labskin-AI data analysis to predict the best course of treatment

Integumen is pleased to announce a cross-platform biophysics agreement with AI developer, Rinocloud Limited, in association with Cork Institute of Technology's Nimbus embedded systems research institute and its Cappa Photonics Laboratory to develop Labskin-On-A-Chip ("LOAC") technology.

 

Labskin-On-A-Chip (LOAC)

Pioneering animal free, clinical research skin-treatment test platform by exploiting Photonics. Labskin is grown on a microchip where light is generated, detected and manipulated, using the cutting-edge use of lasers and fibre-optics on an electro-optical device.

 

Labskin is already a valuable tool for our pharma and skin care clients:

·      Laboratory grown human skin used for testing of skin products and treatments,

·      Can be populated with harmful viruses,

·      Tested using natural skin conditions with good and bad bacteria from patients.

 

LOAC real-time and hands-free can monitor: 

·      Bacteria and virus growth or decline on Labskin – human skin,

·      Balance of good and bad bacteria during skin treatments,

·      The impact on the skin's microflora of skin care products and treatments.

 

RinoLab AI Software:

Combined with the RinoLab/Labskin AI software tools, analysis of the data via Labskin AI client portal can be fed into pharmacodynamic in-silico (pharmaco-dynamic/pharmaco-kinetic) models and used in the pharmaceutical clinical research sector. For clinical research the long-term data accumulated will provide clinical data for new products and skin treatments.

 

World first in skin treatment clinical research. 

Labskin-on-a-Chip as a pre-clinical and post-clinical platform is a major step up for all skin related disease treatments. The completion of the project over the next 12 months is expected to provide every dermatology clinic with a desktop ability to take a swab of the patient's own bacteria, place it on the Labskin and provide the best course of treatment.

 

Fin Murray CEO of Rinocloud commented:

"This is an exciting cross platform development in artificial intelligence at Rinolab and Rinocloud. Our collaboration with Labskin for the AI platform and our work with educational institutions who use Rinocloud has opened up a major opportunity that is set to transform the lives of 3% of the population who suffer daily from skin diseases."

 

Gerard Brandon CEO of Integumen commented:

"Right time, right place, right people, right technology and the right thing to do. In the short time we have been working with the team at Rinocloud we have identified many synergies that bringing together biology, physics, software and most importantly a can-do attitude. I look forward to working closely with the team to rolling this out in late 2019."

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 122 392 6660
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Hybridan LLP  (Broker)	Claire Noyce	+44 (0) 20 3764 2341

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUUUWRWVAUAAA

Close

×

RNS Number : 1700K

Xeros Technology Group plc

12 December 2018

 

RNS Reach

12 December 2018

 

Xeros Technology Group plc

 

Xeros completes outsourcing of Hydrofinity servicing in US

 

Xeros Technology Group plc (AIM: XSG, 'Xeros', 'the Group'), the developer and provider of water saving technologies with multiple commercial applications, has completed the transfer of servicing of Xeros' commercial laundry customers, across the whole of the US, with the signing of a series of regional agreements with full-service distributors. The Group's commercial laundry business is branded Hydrofinity.

 

As previously announced in November with the signing of the first agreement with ELS, these regional distributors will now service all Hydrofinity's existing and future customers in the US with significant savings accruing to Xeros. These distributors will continue to stock and sell Xeros commercial washing machines.

 

Agreements have recently been signed with organisations such as Viking Services to cover California and Consolidated Laundry Equipment Inc to cover the mid-Atlantic region of the US, extending the sales and service coverage of Hydrofinity.

 

This agreement reflects the Hydrofinity strategy to reduce its physical presence in the US market and to move to a licensing model. This model has already been rolled-out in international markets with agreements in place in South Africa, UAE, Australia and China.

 

Mark Nichols, Chief Executive of Xeros, said:

 

"These agreements in the US follow similar agreements recently signed covering China, Dubai and South Africa. They will enable our Hydrofinity business to increase revenues from a lower cost base whilst continuing to provide customers with excellent service."

 

Enquiries:

 

Xeros Technology Group plc   Mark Nichols, Chief Executive Officer   Paul Denney, Chief Financial Officer	Tel: 0114 321 6328
Jefferies International Limited (Nominated Adviser and Joint Broker)   Simon Hardy / Will Soutar	Tel: 020 7029 8000
Berenberg (Joint Broker)   Chris Bowman / Ben Wright / Laure Fine	Tel: 020 3207 7800
Instinctif Partners (Financial PR)   Adrian Duffield / Kay Larsen / Chantal Woolcock	Tel: 020 7457 2020

 

Notes to Editors

 

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes.

 

Xeros' uses its patented XOrbTM technologies to significantly reduce the amount of water used in a number of major applications with the remaining water becoming far more efficient in either affixing or removing molecules from substrates such as fabrics and garments. The result being significant improvements in economic, operational and sustainability outcomes.

 

Xeros has three divisions working in the garment finishing (Textile Technologies), tanning (Tanning Technologies, branded Qualus) and cleaning/laundry (Cleaning Technologies) markets. In cleaning/laundry, the company has three applications covering domestic laundry, commercial laundry (branded "Hydrofinity") and the cleaning of high performance workwear (branded "Marken").

 

For more information, please visit – http://www.xerostech.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRATBBRTMBTBBTP

Close

×

RNS Number : 8912J

e-Therapeutics plc

10 December 2018

 

E-therapeutics Signs Research Collaboration Agreement with Novo Nordisk

 

 

Oxford, UK, 10 December 2018: e-therapeutics plc (AIM: ETX, "e-therapeutics") is pleased to announce a research collaboration with Novo Nordisk under which the companies will use e-therapeutics' proprietary Network-Driven Drug Discovery (NDD) platform to look to discover potentially novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes.

 

Type 2 diabetes currently accounts for approximately 90% of the estimated 425 million people with diabetes globally[1], and new treatments are urgently required to tackle the growing incidence of the condition.

 

Under the Agreement, e-therapeutics will work with Novo Nordisk over a period of 12 months and use its NDD approach to identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies.

 

Jan Nygaard Jensen, Deputy Head of Novo Nordisk Research Center Oxford and Head of Bioinformatics, said: "We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford".

 

e-therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration. Any future license would require mutual agreement of commercial terms. Financial details of the collaboration have not been disclosed.

 

Dr Ray Barlow, CEO at e-therapeutics, said: "We are delighted to be working with Novo Nordisk, a world leader and innovator in diabetes care. This collaboration highlights the use of our Network-Driven Drug Discovery (NDD) platform to understand and potentially create new treatments for complex diseases of great relevance to society, medicine and the industry. Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019."

 

ENDS

 

 

For more information, please contact:

 

e-therapeutics plc Ray Barlow, Chief Executive Officer Steve Medlicott, Finance Director	Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
Numis Securities Limited Michael Meade/Freddie Barnfield (Nominated Adviser) James Black (Corporate Broking)	Tel: +44 (0) 207 260 1000 www.numis.com
FTI Consulting Simon Conway/Brett Pollard	Tel: +44 (0) 203 727 1000 [email protected]

 

About e-therapeutics

 

We are an Oxford, UK-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.

 

Our novel network-driven methodology allows us to discover new and better drugs in a more efficient and effective way.

 

We use our highly productive drug Discovery Engine to develop our own IP-protected, pre-clinical drug discovery programmes which will be of interest to partners looking to acquire or in-license novel and differentiated assets. We are currently developing two programmes in immuno-oncology and have a number of partner-ready projects in areas such as fibrosis and tumour microenvironment.

 

Because of our novel network-driven drug discovery (NDD) approach, we believe there is potential to enter into several different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

 

About Network-Driven Drug Discovery (NDD)

 

e-Therapeutics' proprietary NDD platform comprises a suite of powerful computational tools to augment and interrogate the vast amount of biological information currently available in both public and private databases.

 

Our NDD platform is founded on sophisticated network science and employs techniques such as machine learning, artificial intelligence (AI) and state-of-the-art data analysis tools. Using our biological expertise, we can create and analyse network models of disease to identify likely proteins that could effectively be disrupted to treat the disease.

 

We believe that our network-driven approach more realistically reflects the true complexity of disease, with its multiple and often interconnected cellular pathways. By modelling and analysing disease networks and considering the pattern of connections between proteins, and not just single pathways, we more efficiently select the very best drug-like compounds for screening and for subsequent medicinal chemistry and pre-clinical testing. With our novel methodology, significant numbers of active molecules can be identified and tested quickly. Our approach is highly productive and consistently generates hits that have been progressed into potent, selective and novel drug molecules.

 

Our overall aim is to discover more efficacious drugs more effectively. By using more biologically realistic, cell and tissue-based assays we can choose and design compounds that are more likely to translate into better, more clinically efficacious drugs.

 

 

---

[1] IDF Diabetes Atlas, 8th Edition (2017)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUGGBGPUPRGRB

Close

×

RNS Number : 8910J

ValiRx PLC

09 December 2018

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

UPDATE ON VAL201 CLINICAL TRIAL

"Positive Effect on Cancer Patients"

"Evidence revealed of decrease in prostate cancer biomarker PSA, related to dosing with VAL201"

London, UK., 10 December 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is proud to announce that independent analysis of VAL201 data shows a statistically significant dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

This represents an initial formal statistical analysis of the VAL201 clinical data conducted by Dr Wilson Caparrós-Wanderley, an independent statistical consultant.  This was undertaken using a non-parametric approach – both the well-established 'Friedman Test' (developed by M. Friedman in 1937) and the most up-to-date statistical method, 'Repeated Measures Multiple Correlation Analysis' (refined by Bakdash and Marusich in 2017).

This analysis reveals that volunteers treated with VAL201 display a statistically significant correlation for reductions over time in the amount of Testosterone and Prostate Specific Antigen ("PSA"), both of which are commonly-used markers for disease progression in prostate cancer.

The data further confirms that VAL201 has no statistically significant adverse trends across liver or kidney function.  Furthermore, with no impact on cardiac rhythm in the patients either, this data further reinforces the continuation of the good safety and tolerability data emerging from the trial.

In addition to the independent analysis, the pharmacokinetics information collected from the clinical evaluation of ValiRx's more recent patients, shows that ValiRx is addressing the protocol's primary and secondary endpoints – as well as all the exploratory tertiary end points.

Further information about the endpoints is to be found posted on the NIH website, www.ClinicalTrials.gov, under: 'Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)'.

Dr Satu Vainikka, CEO of ValiRx, commented: "I am delighted to receive this analysis from an external expert, showing that VAL201 is having a positive and desired effect on prostate cancer patients' disease markers.  Effectively, the more a patient takes VAL201, the more a patient's PSA will decrease".

"This is fantastic news and it heralds our entry into the pivotal stage of VAL201's clinical trial programme.  I thank the team for their hard work in delivering these very encouraging and positive outcomes".

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Richard Nash	Tel: +44 (0) 20 7213 0880
Novum Securities Limited (Broker) Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCUKVBRWWAURAA

Close

×

RNS Number : 5952J

Biome Technologies PLC

06 December 2018

 

 

6 December 2018

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

 

Biome Technologies plc, the leading bioplastics and radio frequency technology business, is pleased to announce that it has been awarded a further £0.6 million of grant funding from Innovate UK to support a project focused on pilot-scale production of a novel bioplastic building block.

 

Over the last five years, Biome Technologies has led a £6 million development programme to bring a range of novel highly functional bio-based and biodegradable polymers to market using industrial biotechnology techniques. This programme currently involves seven universities, some 25 scientists and engineers and other partners.

 

Earlier in 2018, the Company reported that the technical feasibility of a number of these potential polymers had been ascertained and that work was now to be focused on establishing the viability of production and commercial scale-up. Following extensive techno-economic analysis this project, one of three key elements of our work in this area, will focus on the scale-up of of PDCA (2,5-pyridinedicarboxylic acid) from bio-based intermediates that can be obtained from the lignin breakdown pathway.

 

This two-year, £0.8 million project in collaboration with the University of Nottingham will use a robust, metabolically diverse organism (Cupriavidus necator) in a contained environment to produce PDCA at pilot-scale. The work uses advanced synthetic biology techniques and state-of-the-art processing for the eventual production of highly biodegradable, compostable and recyclable bioplastic polymers suitable for flexible packaging applications.

 

Biome Technologies CEO Paul Mines commented:

 

"The UK government has set a target of eliminating all avoidable plastic waste by 2042. Bioplastics will play a crucial role in achieving this target by reducing waste. However, current bioplastic technology is limited by price and performance in some applications. Our development programme is intended to change that position by preparing a new generation of polymers with improved functionality."

 

The funding, provided by UK Research and Innovation and delivered by Innovate UK, was awarded as part of a £20 million Open Competition to deliver game changing or disruptive innovations with significant potential for impact on the UK economy.

 

The UK Government's Industrial Strategy sets out 4 Grand Challenges, including Clean Growth, to put the UK at the forefront of the industries of the future. Exemplifying the focus on renewable materials, on 5 December 2018, up to £60 million of new public funding was announced for the Smart Sustainable Plastic Packaging Challenge, through the Industrial Strategy Challenge fund. Illustrating economic  potential of such products, a recent report by bioeconomy consultants NNFCC found that plastics made from plants instead of oil, many of which are biodegradable – could create 34,000 jobs and contribute £1.92 billion to the UK economy in the next decade.

 

More information about the Group's work in this area can be found at www.biomebioplastics.com/industrial-biotechnology.

 

  

– Ends –

For further information please contact: Biome Technologies plc
Paul Mines, Chief Executive Officer
Declan Brown, Group Finance Director
www.biometechnologiesplc.com	Tel: +44 (0) 2380 867 100
Allenby Capital
David Hart/Alex Brearley (Nominated Adviser) Kelly Gardiner (Broker)
www.allenbycapital.com	Tel: +44 (0) 20 3328 5656

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

 

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

 

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

·      Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

·      Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

·      Increase investment in the Group's next generation of products by spending significantly more per annum on average than the £0.3m per annum average spend over the previous strategic objective cycle

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAEAPASEEEPFFF

Close